Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial Journal Article
| Authors: | Mahadeo, K. M.; Baiocchi, R.; Beitinjaneh, A.; Chaganti, S.; Choquet, S.; Dierickx, D.; Dinavahi, R.; Duan, X.; Gamelin, L.; Ghobadi, A.; Guzman-Becerra, N.; Joshi, M.; Mehta, A.; Navarro, W. H.; Nikiforow, S.; O'Reilly, R. J.; Reshef, R.; Ruiz, F.; Spindler, T.; Prockop, S. |
| Article Title: | Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial |
| Journal Title: | Lancet Oncology |
| Volume: | 25 |
| Issue: | 3 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-03-01 |
| Start Page: | 376 |
| End Page: | 387 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(23)00649-6 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 38309282 |
| DOI/URL: | |
| Notes: | Accession Number: 175643595 -- Entry Date: In Process -- Revision Date: 20240227 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 100957246. -- Source: Cinahl |
